GenScript ProBio Congratulates ABL Bio's IND Clearance of AB

Recently, ABL Bio, a partner of GenScript ProBio, announced the Ministry of Food and Drug Safety (MFDS) cleared of its clinical trial application for innovative bispecific antibody program (B7H4x4-1BB) in solid tumor. GenScript ProBio warmly extends congratulations on this major milestone achievement. In this ABL103 program, GenScript ProBio provided the service of process development & optimization, clinical material manufacturing, and CTD documentation preparation for MFDS IND filing.

Related Keywords

Nanjing , Jiangsu , China , Hong Kong , Shanghai , United States , Netherlands , South Korea , Asia Pacific , Patrick Liu , Hoon Lee , Genscript Probio , Genscript Biotech Corporation , Emergency Use Authorization , Sang Hoon Lee , Script Probio , Mfds , Bispecific Antibody , Avrobio , Clinical Trial Application , Genscript ,